Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9068019
APP PUB NO 20120251486A1
SERIAL NO

13502675

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HANALL BIOPHARMA CO LTD400-1 SANGSEO-DONG DAEDEOK-GU DAEJEON 306-120

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jeong, Jae Kap Suwon-si, KR 19 18
Jun, Sung Soo Seongnam-si, KR 39 261
Kim, Eun Sun Suwon-si, KR 187 3293
Kim, Ha Na Suwon-si, KR 52 379
Kim, Song Young Suwon-si, KR 4 7
Kim, Sung Wuk Seongnam-si, KR 51 282
Park, Seung Kook Seoul, KR 24 20
Song, Yeon Jung Yongin-si, KR 15 15

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 30, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00